Breast Cancer

Metastatic breast cancer vaccine trial to continue

Published in Vaccine Weekly, November 27th, 2002

Biomira, Inc., (BIOM), of Edmonton, Alberta, Canada, and Merck KGaA of Darmstadt, Germany, announced that they will continue their phase III clinical trial of Theratope vaccine through its planned conclusion in 2003.

This decision was made based on a recommendation from an independent review of interim data from their double-blinded randomized trial conducted in 1030 women with metastatic breast cancer. Theratope vaccine has fast-track designation with the U.S. Food and Drug Administration (FDA) for the treatment of metastatic breast cancer.

The Data Safety Monitoring board (DSMB) stated that they had "no safety concerns at all and recommend that...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-11-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry